BACE1 inhibitors

US9540397B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Bjoern Bartels · Schopfheim, DE
• Philipp Cueni · Basel, CH
• Cosimo Dolente · Allschwil, CH
• Wolfgang Guba · Memmingen, DE
• Wolfgang Haap · Bad Kötzting, DE
• Andreas Kuglstatter · Soest, DE
• Ulrike Obst Sander · Sursee, CH
• Jens-Uwe Peters · Weil am Rhein, DE
• Mark Rogers-Evans · Bottmingen, CH
• Walter Vifian · Gelterkinden, CH
• Thomas Woltering · Freiburg (Elbe), DE

Key dates

• Filing date: Oct 7, 2015
• Grant date: Jan 10, 2017
• Expiry date: Oct 7, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.